News and notes from around the interweb:
- Optimistic take – the pandemic may be over in a few months, not just from running through the population and because we have vaccines, but three legit treatments that’ll keep people from ever being hospitalized once they test positive. Fluvoximine is a cheap and readily available anti-depressant. The Merck transcriptase inhibitor molnupiravir are really good. And the Pfizer protease inhibitor – “the first small molecule trial results from a compound that was explicitly aimed at a SAR-CoV-2 protein” – are incredible, too, reducing hospitalizations 90% in a trial and deaths by 100%.
We don’t know pricing yet from Pfizer but they’ve made some nods towards affordability, the Merck pill would be offered cheaply in developing countries, and fluvoximine is already more or less accessible. And they may even work as a cocktail, reducing changes of a resistant strain. (The Merck compound is unlikely to face this issue in any case.)
- Filmmaker whose cash was stolen by the DEA at a TSA checkpoint got all his money back plus legal fees. It took eight months.
- People around the world who’ve taken the Sputnik and CanSino vaccines are scurrying to get re-vaccinated in order to visit the U.S.. The U.S. will accept the largely ineffective SinoVac CoronaVac (which the World Health Organization says shows no evidence of reduction in infection or transmission, but reduced symtomatic infection by 51% in a messy trial before the Delta variant).
- The Pete Buttigieg slush fund included in the infrastructure bill
- Keep Checking IHG Award Prices for Price Drops, Then Rebook or use Free Night Certificates once Marriott goes ‘dynamic’ for award pricing in March they’ll be adjusting prices of room nights more frequently, too, and you’ll need to keep repricing those as well.
- Just a coincidence that advertising for the new American Airlines outsourced curbside check-in fee is in Spirit Airlines yellow?